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Dan Carter carefully layered the sheets of trac-ing paper on the light box. On each sheet were renderings of the atomic components of an 
essential human protein, one whose structure had long 
been a mystery. With each layer Carter laid down, a 
never-before-seen image became clearer. 
Carter joined NASA’s Marshall Space Flight Center 
in 1985 and began exploring processes of protein crys-
tal growth in space. By bouncing intense X-rays off the 
crystals, researchers can determine the electron densities 
around the thousands of atoms forming the protein 
molecules, unveiling their atomic structures. Cultivating 
crystals of sufficient quality on Earth was problematic; the 
microgravity conditions of space were far more accommo-
dating. At the time, only a few hundred protein structures 
had been mapped, and the methods were time consuming 
and tedious. Carter hoped his work would help reveal 
the structure of human serum albumin, a major protein 
in the human circulatory system responsible for ferrying 
numerous small molecules in the blood.
More was at stake than scientific curiosity.
“Albumin has a high affinity for most of 
the world’s pharmaceuticals,” Carter 
explains, “and its interaction with drugs 
can change their safety and efficacy.” 
When a medication enters the 
bloodstream—a cancer 
chemotherapy drug, for 
example—a majority of 
it can bind with albumin, 
leaving only a small 
percentage active for 
treatment. How a drug 
interacts with albumin can 
influence considerations like 
the necessary effective dosage, playing a 
significant role in the design and application 
of therapeutic measures. 
In spite of numerous difficulties, including 
having no access to microgravity following the 
1986 Space Shuttle Challenger disaster, the image 
Carter had hoped to see was finally clarifying. In 1988, 
his lab had acquired specialized X-ray and detection 
equipment—a tipping point. Carter and his colleagues 
began to piece together albumin’s portrait, the formation 
of its electron densities coalescing on the sheets of tracing 
paper he arranged on the light box. While space-grown 
crystals were ultimately not involved in the achievement, 
a year later, Carter says, “we were on the cover of Science 
magazine, having determined the atomic structure of 
albumin.” 
partnership
The albumin mapping project began to reveal 
important aspects of how the protein bound with and 
transported drugs. After a number of years studying the 
formerly inscrutable molecule, it became apparent to 
Carter and a number of his colleagues that the potential 
of this knowledge to impact drug design and develop-
ment was too great to ignore. In 1997, they founded New 
Century Pharmaceuticals Inc., based in Huntsville, 
Alabama, to launch a large-scale structural biology pro-
gram to map at an atomic resolution the structures of 
drugs bound to albumin, with the intent to improve drug 
performance. 
Over the following years, New Century continued to 
work with NASA through a series of grants and contracts 
in support of the Agency’s protein crystal growth in 
microgravity program. Several inventions discovered at 
NASA were also licensed to New Century so Carter and 
his team could continue to test and develop its albumin-
based innovations. The company also developed a unique 
set of technologies based on the original albumin break-
through. 
Benefits
Today, New Century’s Crystallography and Albumin-
based Drug Design and Evaluation platform, or CADEX, 
is the world’s most extensive library of atomic structures 
demonstrating the binding characteristics of drugs and 
albumin. Covering over 25 therapeutic categories from 
antidepressants to anti-cancer agents to antihistamines, 
CADEX provides a comprehensive knowledge base for 
the development of drugs tailored to interact effectively 
with albumin. 
As an outcome of compiling CADEX, New Century 
was able to create a number of other innovations with 
A surface rendering of the 
atomic structure of human 
serum albumin, illustrating 
charge distribution. NASA 
researchers at Marshall 
Space Flight Center were 
the first to map the atomic 
structure of albumin, an 
important blood protein.
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potential for medical benefit, including its first commercial 
product, Albagen recombinant human serum albumin 
(rHSA). Produced synthetically in yeast rather than derived 
from animal sources, the Albagen rHSA is hypoallergenic 
and poses no risk of dangerous contaminants like viruses or 
prions. New Century licensed the Albagen technology to 
Albumin Bioscience in 2009, which is expanding the appli-
cation of Albagen into potential research and therapeutic 
markets including drug delivery and in vitro fertilization. 
Albumin Bioscience has also incorporated Albagen into a 
line of unique skin care products designed to improve skin 
health by replenishing albumin levels in the skin. 
Meanwhile, New Century continues to build upon the 
foundation of its CADEX repository. 
“We learned that the bulk of large complex antican-
cer drugs bind to the same location in albumin,” says 
Carter, who served as chief of Marshall’s Biophysics 
and Advanced Materials Branch and won multiple 
NASA honors before founding New Century. “We also 
learned of molecules that have no anticancer activity 
and which are very powerful in blocking that particular 
binding site.” 
The outcome is a new cancer drug combination 
approach called Salus, which in effect “tunes” the patient’s 
blood chemistry so that less of the anticancer drugs bind 
with albumin. This results in lower dose requirements—
good news for patients who suffer from the toxic side 
effects of chemotherapy. The company plans to start clini-
cal trials this year. 
“When we look at the activity against cancer cell lines, 
there is dramatic improvement in performance,” says 
Carter. “Our goal is that this will be used to improve the 
clinical outcome of cancer patients everywhere.” 
New Century has cultivated a number of successes out-
side of its albumin research. At Marshall in 1991, Carter, 
NASA colleague Joseph X. Ho and Florian Rüker, then 
with the Institute of Applied Microbiology in Vienna, 
helped determine the atomic structure of an antibody that 
recognized HIV—another scientific first. This collabora-
tion culminated in a modular antibody technology that the 
company licensed and later sold to Austrian biotechnology 
company f-star, which is using the innovation to develop 
novel antibody-based treatments for conditions ranging 
from cancer to autoimmune diseases. New Century also 
invented a family of nanoparticle protein technologies, 
Ferrigen, with potential applications ranging from vac-
cines to drug delivery; developed a candidate HIV vaccine 
platform utilizing the Ferrigen technology; and crafted 
hardware currently under testing at Marshall for growing 
large crystals in space—ideal for neutron imaging applica-
tions that can reveal atomic structures more clearly than 
ever before. 
With its origins at NASA, New Century’s CADEX 
platform is still the world’s largest repository of albumin 
structures, Carter says, and the potential clinical benefit of 
that data has yet to be fully realized.
“The challenge ahead of us is how that information 
is translated into helping people,” he says. “That’s an 
ongoing process.” v
CADEX™, Albagen™, Salus™, and Ferrigen™ are trademarks of 
New Century Pharmaceuticals Inc.
“Our goal is that this will be used to  
improve the clinical outcome of cancer 
patients everywhere.”
—Dan Carter, New Century Pharmaceuticals
New Century Pharmaceuticals Inc. has built upon the original NASA work on albumin to develop a new cancer drug combination 
approach that promises to improve anticancer drug performance and diminish the toxic side effects of chemotherapy.
